Nanotech Policy Environment at FDA and NGO responses Ian S. Illuminato Friends of the Earth Collaborative on Health and the Environment (CHE) Partnership.

Slides:



Advertisements
Similar presentations
EPA Field Activities Relating to Nanoscale Materials Bradley R. Grams, Environmental Scientist Chemicals Management Branch Land and Chemicals Division,
Advertisements

Nanotechnology and Nanomaterials in Consumer Products: Regulatory Challenges and Necessary Amendments George A. Kimbrell The International Center for Technology.
Canada/Australia Issues being faced in the regulation of nano-materials Deborah Willcocks – Department of Health and Ageing, Government of Australia Anne-Marie.
U.S. Science Policy Cheryl L. Eavey, Program Director
Nanotechnology: an integrated product policy approach Rosalind Malcolm Professor of Law School of Law University of Surrey UK.
Health IT Standards Committee Federal Health IT Strategic Plan December 10, 2014 Seth Pazinski Director, Office of Planning, Evaluation, and.
Consumer Work Group Presentation Federal Health IT Strategic Plan January 9, 2015 Gretchen Wyatt Office of Planning, Evaluation, and Analysis.
FDA’s Policy for Evaluating Bioengineered Foods Jeanette Glover Glew Food and Drug Administration Center For Food Safety and Applied Nutrition September,
Ohio Nano-Summit March 3, 2005 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D. Associate.
The Role of Biotechnology in a Sustainable Food Supply Section 3 : Risk Assessment Peggy G. Lemaux, University of California, Berkeley, California, U.S.A.
The Toxic Substances Control Act (TSCA) Interagency Testing Committee (ITC)
Nanotechnology Documentary Standards Activities Ajit Jillavenkatesa Standard Services Division NIST April 30, 2008.
The Changing Food Environment The Role and Activities of the U.S. Food and Drug Administration Transatlantic Consumer Dialogue The Changing Food Environment.
Jake Blanchard – University of Wisconsin – August 2007.
David Rejeski Director, Project on Emerging Nanotechnologies Woodrow Wilson International Center for Scholars October 10, 2006 FDA and Nanotechnology:
Conference on NANO-Safety 22-24, April,2009 Ljubljana, Slovenia NANOTECHNOLOGY A challenge or a threat? The Perspective of NGOs Paschalidis Georgios Pan-Hellenic.
CPSC Lead Program: Regulations, Guidance, and Outreach Frank J. Nava U.S. Consumer Product Safety Commission January 26, 2006 These comments are those.
Nanomaterials Issue Paper Standard 61 Joint Committee Meeting December, 2013.
Regulations Lord’s Prayer 66 words Gettysburg Address 286 words Declaration of Independence 1,322 words Federal regulations on the sale of cabbage 26,911.
SBIR/STTR Programs Introduction John Ujvari, MBA SBIR Program Specialist North Carolina SBTDC Phone: Web:
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
A. H. Carim, Co-chair, NSET Subcommittee of NSTC1 Activities in the National Nanotechnology Initiative Dr. Altaf H. Carim Co-chair Nanoscale Science, Engineering,
Nanomaterials in Consumer Products and FDA Regulation George A. Kimbrell The International Center for Technology Assessment Nano & Bio In Society Conference.
1 Update on Nanotechnology Activities in CDER and FDA Keith O. Webber, Ph.D. Deputy Director OPS/CDER/FDA ACPS Meeting Tuesday, July 22, 2008.
NS 440 LEGAL AND REGULATORY ENVIRONMENT IN FOOD PRODUCTION SPRING YOUNTS DAHL, MS PHD INSTRUCTOR Unit 5: Policy Considerations in Food Regulation.
The Only Government-wide Forum for Technology Transfer FLC Washington DC Office Gary K. Jones FLC Washington DC Rep FLC Mid-Atlantic Regional Meeting Rocky.
World Congress on Safety and Health at Work Korea Promoting Safe Use of Nanotechnologies in Australian Workplaces: Nanotechnology OHS Research and.
Nanosciences and nanotechnologies: European Action
Deemed Exports Overview and the Inspector General’s Report Presentation for : Alex Lopes Director, Deemed Exports and Electronics Division Office of National.
Objective 2.03 Explain how the United States Constitution grants and limits the authority of public officials and government agencies. I: What is the Federal.
1 FDA Perspective on Nanomaterial- Containing Products Nakissa Sadrieh, Ph.D. Associate Director for Research Policy and Implementation Office of Pharmaceutical.
Nano-materials: Environmental and Health Impacts Chem Eng Progress: 104 (12), , 2008.
The role of Future-oriented technology analysis in the governance of emerging technologies: The example of nanotechnology Petra Schaper-Rinkel AIT Austrian.
Introduction to a Safe Workplace
The Executive Branch NEXT. Section 1: The Presidency The president and the vice president are required to have certain qualifications. Reading Focus What.
Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.
1 Nanoscale Materials Stewardship Program Environmental Summit May 20, 2008 Jim Alwood Chemical Control Division Office of Pollution Prevention and Toxics.
Genetically Modified Foods Beth Roberson November 19, 2004 FST 490.
Office of Science Office of Science Advisory Committee Chairs Perspectives on the Department of Energy Office of Science - Issues and Opportunities in.
NITRD Networking and Information Technology Research and Development Program 19 March 2009.
Special Meeting on Procedures for Information Exchange November 7, 2007 Geneva Session 1 Anne Meininger United States USA WTO TBT Enquiry Point.
Executive Branch The Cabinet and Federal Agencies.
Technology Services – National Institute of Standards and Technology Facilitating Global Markets: NIST Dialogue with Regulators Mary Saunders Chief, Standards.
Dennis Utterback Office of Research and Development U.S. Environmental Protection Agency Federal Environmental Symposium June 6, 2007 Understanding the.
Nora Savage, PhD US EPA, Office of Research & Development National Center for Environmental Research Environmental Engineering Research Division EPA STAR.
Overview of the Nanotechnology Industry: Drivers & Demand.
Lecture #4 Risk Assessment, philosophical approaches to risk & regulation.
INTRODUCTION TO OSHA Lesson
Chapter 7: The Executive Branch at Work Section 2: Executive Departments and Independent Agencies (pgs )
The Cabinet and Federal Agencies
The Executive Branch NEXT.
LOW LEVEL RADIOACTIVE WASTE FORUM--FALL 2014 MEETING
Chapter 6 The Executive Branch
Academic Challenges Concerning Standardization
What we all need to know about the powers that be!
Chapter 6 The Executive Branch
GENE EDITING: Regulatory & IP Considerations
Independent Agencies & Cabinet Departments
Sequential Phase II Awards at the Department of Energy
From Lab to Label: Innovations That Feed The World
Executive Branch Chapter 15 The Bureaucracy – Government at Work
Executive Office of the President (EOP)
Allen Chan U.S. Government Accountability Office October 2, 2018
Chapter 6 The Executive Branch
Tobey Clark, Director*, Burlington USA
Introduction of the new Canada Consumer Product Safety Act
Chapter 6 The Executive Branch
Bureaucracies and Regulatory Agencies
Bellringer What is the process for Presidential Impeachment?
Care of Research Animals
Presentation transcript:

Nanotech Policy Environment at FDA and NGO responses Ian S. Illuminato Friends of the Earth Collaborative on Health and the Environment (CHE) Partnership Call Health and Medicine: the Impacts of Nanotechnology October 11, 2007

Friends of the Earth is the U.S. voice of an influential, international network of grassroots groups in 70 countries. Founded in San Francisco in 1969 by David Brower, Friends of the Earth has for decades been at the forefront of high-profile efforts to create a more healthy, just world. Our members were the founders of what is now the world's largest federation of democratically elected environmental groups, Friends of the Earth International.

Nanotechnology and the U.S. Government NSET NTSC's CT NNI Nanoscale Science, Engineering and Technology Subcommittee National Nanotechnology Initiative National Science and Technology Council’s Committee on Technology

23 Federal agencies participate in the National Nanotechnology Initiative (NNI) Consumer Product Safety Commission USDA/FS Department of Commerce Bureau of Industry and Security, Technology Administration Department of Commerce, National Institute of Standards and Technology Department of Defense Department of Education Department of Energy Office of Science, Office of Basic Energy Sciences, Office of Fossil Energy, Office of Industrial Technologies Department of Health and Human Services, National Institutes of Health FDA NIOSH Department of Homeland Security Department of Justice Department of Labor Department of State Department of Transportation Department of Treasury EPA Intelligence Community International Trade Commission NASA National Science Foundation Nuclear Regulatory Commission Patent and Trade Mark Office NNI website:

NNI Agencies with R&D Budgets for Nanotechnology Department of Commerce, National Institute of Standards and Technology Department of Justice Department of Defense Environmental Protection Agency Department of Energy National Aeronautics and Space Administration National Institutes of Health National Science Foundation National Institute for Occupational Safety and Health Department of Agriculture (USDA), Cooperative State Research, Education, and Extension Service Department of Homeland Security Department of Transportation NNI website:

Agency 2001 Actual2002 Actual2003 Actual2004 Actual2005 Actual NSF DOD DOE DHHS (NIH) DOC(NIST) NASA EPA56557 USDA123 DHHS (NIOSH)3 DOJ11122 DHS2111 TOTAL Adapted from NNI website chart: NNI Budget History by Agency (dollars in millions)

Agency2006 Actual2007 Estimate2008 Proposed NSF DOD DOE DHHS (NIH) DOC(NIST) NASA EPA USDA (CSREES) DHHS (NIOSH) USDA/FS DHS DOJ DOT (FHWA)0.9 TOTAL Adapted from NNI website chart:

Budget for Environmental, Health, and Safety R&D, (dollars in millions) Agency2006 Actual2007 Estimate2008 request NSF DOD1.0 DOE DHHS (NIH) DOC(NIST) NASA0.0 EPA USDA (CSREES)0.1 DHHS (NIOSH) USDA/FS0.0 DHS0.0 DOJ0.0 DOT (FHWA)0.0 TOTAL Adapted from NNI’s Supplement to the President’s 2008 Budget.

Nanotech EHS Spending Must Increase Substantially EHS currently only 4% of NNI’s annual $1 billion budget Biggest chunk of NNI’s annual budget goes to Department of Defense [2006: $423.9 million] EPA received only $4.5 million budget from NNI in 2006 $8.3 billion spent on nano since NNI request for EHS budget is $58.6 million, an increase of 55% from 2006 spending: NOT ENOUGH!

FDA is charged with regulating the safety and effectiveness of most food, drugs, and cosmetics, as well as other substances such as medical devices, animal feed, and combination products (21 U.S.C. Ch. 9 et seq.) –Many currently available nano-products fall under FDA’s broad regulatory scheme –Cosmetics (21 U.S.C. § 361 et seq) –Sunscreens (21 U.S.C. § 321(g)) (classified as human drugs)

Nanotech’s History at FDA Early 2005: Under the National Cancer Institute’s (NCI’s) Alliance for Nanotechnology in Cancer, FDA works to accelerate nano cancer applications. FDA and NCI join forces under the nano-subcommittee of the Interagency Oncology Task Force (IOTF). May 16th 2006: International Center for Technology Assessment (ICTA) and Friends of the Earth (FoE) file citizen petition with FDA. August 2006: FDA launches its own FDA Nanotechnology Task Force “to identify and recommend ways to address knowledge or policy gaps to facilitate the safe and effective use of nanoengineered materials in FDA-regulated products.”

October 10 th 2006: FDA’s Task Force “first success,” FDA holds public meeting on nanotechnology, widely attended by NGO community and many presentations and comments submitted. July 25 th 2007: As promised at the Oct public meeting, FDA releases report Nanotechnology: A Report of the U.S. Food and Drug Administration Nanotechnology Task Force. August 2007: FDA proposes new sunscreens regulations that focus on sunscreen protection from UVA light. –As part of the proposal FDA has also solicited public comment on the safety and effectiveness of nano-sunscreens “because of the potential risk of nanoparticle ingredients penetrating consumers’ skin.” FDA also helps lead efforts on nano with a number of other organizations and working groups: NNI, NSET, NEHI, NPEG, GIN.

Citizen Petition to the US FDA First-ever Legal Action On Risks Of Nanotechnology May 2006: ICTA, FoE and coalition of consumer, health, and environmental groups file legal petition challenging FDA’s failure to regulate human health and environmental threats from nanomaterials. (Photo by David Hawxhurst-Woodrow Wilson International Center for Scholars.)

The petition calls for: Comprehensive nanomaterial-specific regulations New paradigms of nano-specific toxicity testing Classification of nanomaterials as new substances Mandatory nanomaterial product and ingredient labeling Compliance with the National Environmental Policy Act (NEPA)

Petition Focus: Nano-sunscreens Sunscreens are classified by FDA as human drugs and should be subject to rigorous pre-market regulation. Red flags regarding free radical creation and DNA damage; unanswered questions about skin penetration. Despite their unique dangers and patented differences, FDA currently considers nano-sunscreens equivalent to bulk material sunscreens. Petition calls for nano-sunscreen recall until manufacturers submit and FDA reviews pre-marketing testing data proving the drugs’ safety and efficacy.

Friends of the Earth Nanomaterials, Sunscreens and Cosmetics Report –At least 116 cosmetics, sunscreens, and personal care products containing nanomaterials commercially available. Friends of the Earth Nanotechnology and Sunscreens Report –Surveyed more than 150 sunscreen manufactures on use of nanoparticles –After release, FDA opens comment period on nanotechnology in sunscreens, “because of the potential risk of nanoparticle ingredients penetrating consumers’ skin.” Recent Friends of the Earth Reports on Nanotechnology in Personal Care Products

The Nanotechnology Task Force Report: is this all we get? The report and the Oct public meeting are FDA’s biggest contributions to nano regulation and oversight thus far. The Task Force Report highlights comments received during the public meeting and comment period, yet excludes nearly all of them in its recommendations. FDA’s interpretation of “safety” is far from NGO position and could compromise human and environmental health. FDA relies to heavily on industry to assure nano product safety. FDA refuses to label nano products, compromising a consumers’ freedom to choose by his or her own judgment what is safe and healthy.

Task Force Report Statements Vs. Recommendations/Claims FDA states: FDA admits nano health risks: “Because of some of their special properties, nanoscale materials may pose different safety issues than their larger or smaller (i.e., molecular) counterparts.” FDA recommends/claims: No labeling: “because the current science does not support a finding that classes of products with nanoscale materials necessarily present greater safety concerns than classes of products without nanoscale materials.”

FDA states: “Developing a comprehensive description of products that are currently produced with nanotechnology…would be difficult at best, and likely infeasible.” Wilson Center’s Project on Emerging Nanotechnologies did it (2007): 500+ self-identified nano-products currently on the market. FDA recommends/claims: “The Task Force has considered a broad array of available information on a wide range of products, materials, techniques, and technologies.” What products? From what information? (Photo by David Hawxhurst-Woodrow Wilson International Center for Scholars.)

Conclusion FDA must employ the precautionary principle for nano-products regulation: FDA highlights the fact that some “available information does not suggest that all materials with nanoscale dimensions will be hazardous,” which does not mean that many nano materials will not be hazardous. Adequate Regulation: A regulatory framework is needed that protects workers, the general public and the environment from the impacts of nanomaterials throughout their lifecycle. – FDA is not regulating nanotechnology. Why do they claim they are?

Learn from the past: FDA must act quickly if it hopes to avoid repeating the mistakes of past federal agency regulatory failures of “wonder” materials or technologies (e.g., asbestos, CFCs, DDT, PCBs, GMOs) Much more robust EHS Study: Adequate, publicly available, independent, peer-reviewed safety studies on the environmental and health impacts of nanomaterials FDA must not rely on voluntary programs: human and environmental health should not be left in the hands of industry.

For More Information: Ian Illuminato Health and Environment Campaigner Friends of the Earth US 1717 Massachusetts Avenue NW, Suite 600 P: F: E:

Resources Friends of the Earth US and Australia: and Woodrow Wilson International Center for Scholar’s Project on Emerging Nanotechnologies: Natural Resources Defense Council (NRDC): National Nanotechnology Initiative (NNI):